Patrick Lamy - 10 Jun 2025 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Reporting owner
Signature
/s/ Jonathan Young, Attorney-in-Fact
Issuer context
Transaction snapshot
SEC evidence
Form type
4
Filing time
12 Jun 2025, 18:32:59 UTC
Previous filing
04 Jun 2025
Next filing
20 Jun 2025
SEC filing
View on sec.gov

Key filing fact

Patrick Lamy filed Form 4 for Akero Therapeutics, Inc. (AKRO) on 12 Jun 2025.

Key facts

  • This page summarizes Patrick Lamy's Form 4 filing for Akero Therapeutics, Inc. (AKRO).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Filing timestamp: 12 Jun 2025, 18:32.

Change

  • Previous filing in this sequence was filed on 04 Jun 2025.
  • Current net transaction value: -$49,625.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reporting Owners (1)

CIK 0001961273 Primary reporting owner

Lamy Patrick

Relationship
Senior VP, Commercial Strategy
Address
C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BLVD, SUITE 350, SOUTH SAN FRANCISCO
Signature
/s/ Jonathan Young, Attorney-in-Fact
Signature date
12 Jun 2025

Reported transactions

AKRO transaction

Common Stock

Sale

Transaction value
$49,625
Shares
-919
Change %
-2.7%
Price
$54.00
Shares after
32,573
Date
10 Jun 2025
Ownership
Direct
Footnotes
F1, F2
* indicates a reported price that failed the local validity check.

Explanation of Responses:

Id Content
F1 Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. Such sales were automatic and not at the discretion of the Reporting Person.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $53.93 to $54.00, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .